Spinal gabapentin is antinociceptive in the rat formalin test

Neuroscience Letters

Volumn 222, Issue 1, 1997, Pages 65-67

  Shimoyama, Naohito ^a,b   Shimoyama, Megumi ^a,b   Davis, Antonia M ^a,b   Inturrisi, Charles E ^a,b   Elliott, Kathryn J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antinociception; Formalin; Gabapentin; spinal administration

Indexed keywords

ANTICONVULSIVE AGENT; FORMALDEHYDE; GABAPENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRATHECAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ACETIC ACIDS; AMINES; ANIMALS; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; INJECTIONS, SPINAL; MALE; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031020305     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)13331-6     Document Type: Article

References (18)

1. Coderre, T.J., Katz, J., Vaccarino, A.L. and Melzack, R., Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence, Pain, 52 (1993) 259-285.
2. Coderre, T.J., Vaccarino, A.L. and Melzack, R., Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection, Brain Res., 535 (1990) 155-158.
3. Elliott, K., Taxonomy and mechanism of neuropathic pain, Semin. Neurol., 14 (1995) 195-205.
4. 2δ subunit of a calcium channel, J. Biol. Chem., 271 (1996) 5768-5776.
5. Mellick, G.A. and Mellicy, L.B., Gabapentin in the management of reflex sympathetic dystrophy, J. Pain Sympt. Manage., 10 (1995) 265-266.
6. Ramsey, R.E., Clinical efficacy and safety of gabapentin, Neurology, 44 (1994) S31-S32.
7. Rock, D.M., Kelly, K.M. and Macdonald, R.L., Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons, Epilepsy Res., 16 (1993) 89-98.
8. Segal, A.Z. and Rordorf, G., Gabapentin as a novel treatment for postherpetic neuralgia, Neurology, 46 (1996) 1175-1176.
9. Székely, J.I., The most characteristic in vivo effects of opiates. In J.I. Székely and A.Z. Rónai (Eds.), Opioid Peptides, Vol. 1, CRC Press, Boca Raton, FL, 1982, pp. 29-109.
10. Shimoyama, M., Shimoyama, N., Inturrisi, C.E. and Elliott, K.J., Oral ketamine produces a dose-dependent CNS depression in the rat, Life Sci., 60 (1996) PL9-PL14.
11. Shimoyama, N., Shimoyama, M., Inturrisi, C.E. and Elliott, K.J., Ketamine attenuates and reverses morphine tolerance in rodents, Anesthesiology, 85 (1996) in press.
12. 3H]gabapentin binding to a novel site in rat brain: homogenate binding studies, Eur. J. Pharmacol. Mol. Pharmacol., 244 (1993) 293-301.
13. 3H]gabapentin to a novel site in rat brain: autoradiographic studies, Eur. J. Pharmacol. Mol. Pharmacol., 244 (1993) 303-309.
14. Taylor, C.P., Vartanian, M.G., Yuen, P.W., Bigge, C., Suman-Chauhan, N. and Hill, D.R., Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin, Epilepsy Res., 14 (1993) 11-15.
15. Taylor, C.P., Emerging perspectives on the mechanism of action of gabapentin, Neurology, 44 (1994) S10-S16.
16. The US Gabapentin Study Group, The long-term safety and efficacy of gabapentin (neurontin) as add-on therapy in drug-resistant partial epilepsy, Epilepsy Res., 18 (1994) 67-73.
17. Yaksh, T.L. and Malmberg, A.B., Central pharmacology of nociceptive transmission. In P.D. Wall and R. Melzack (Eds.), The Textbook of Pain, Churchill Livingstone, London, 1994, pp. 165-200.
18. Yamamoto, T. and Yaksh, T.L., Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat, Anesthesiology, 77 (1992) 757-763.